AIM
AIM ImmunoTech Inc.
There isn't enough reported data to score AIM yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AIM Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Unavailable | |
| Unavailable |
AIM's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AIM PE Valuation
AIM has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AIM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect AIM's losses to shrink, with revenue declining.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
AIM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$7.79 | +$11.85 |
| Q2 2026 | -$9.10 | +$14.84 |
| Q1 2026 | -$12.24 | +$11.04 |
| Q4 2025 | -$16.40 | +$13.67 |
| Q3 2025 | -$19.64 | +$25.95 |
| Q2 2025 | -$23.94 | +$31.35 |
| Q1 2025 | -$23.28 | +$38.80 |
| Q4 2024 | -$30.07 | +$28.13 |
AIM has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
AIM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $22K | -15% |
| Q2 2026 | $26K | +4% |
| Q1 2026 | $22K | +38% |
| Q4 2025 | $21K | -53% |
| Q3 2025 | $26K | -26% |
| Q2 2025 | $25K | -50% |
| Q1 2025 | $16K | -60% |
| Q4 2024 | $45K | -31% |
AIM's revenue has slid since its 2023 peak: $22,000 last quarter, down 15% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -13441% | -4029 points |
| Q2 2026 | -13512% | -2928 points |
| Q1 2026 | -10118% | +12501 points |
| Q4 2025 | -14057% | -1046 points |
| Q3 2025 | -9412% | +3414 points |
| Q2 2025 | -10584% | -3196 points |
| Q1 2025 | -22619% | -8284 points |
| Q4 2024 | -13011% | +8534 points |
AIM's operating margin was −13441% last quarter, down 4029 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over AIM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over AIM on profitability, with a higher operating margin.
AIM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$4.6M | -$3.1M |
| Q1 2026 | -$2.7M | -$358K |
| Q2 2025 | -$1.5M | +$1.5M |
| Q1 2025 | -$2.4M | +$2.5M |
| Q2 2024 | -$3M | -$850K |
| Q1 2024 | -$4.8M | -$1.1M |
| Q4 2021 | -$5.8M | -$2.9M |
| Q3 2021 | -$3.5M | -$472K |
AIM has burned cash in almost every quarter: −$12M over the past year, against −$14M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
AIM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +90% | +15.4M shares |
| 1 year | +4051% | +31.7M shares |
| 3 years | +6411% | +32M shares |
| 5 years | +8001% | +32.1M shares |
AIM has 32M diluted shares, up 4051% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over AIM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
AIM Net Leverage
AIM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
AIM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.7 | Oversold |
| Stochastic | 5.5 | Oversold |
AIM's weekly RSI is 29 (oversold) and its Stochastic is 6 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AIM PE vs Healthcare Sector
AIM has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
AIM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.17 | 12% below |
| 20 week MA | $0.22 | 32% below |
| 50 week MA | $0.58 | 74% below |
| 100 week MA | $4.33 | 97% below |
| 200 week MA | $22.8 | 99% below |
AIM is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AIM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $50.8 | $195.0 | +284% |
| 2021 | $195.0 | $103.8 | -47% |
| 2022 | $103.8 | $34.8 | -66% |
| 2023 | $34.8 | $41.4 | +19% |
| 2024 | $41.4 | $19.8 | -52% |
| 2025 | $19.8 | $1.25 | -94% |
| 2026 YTD | $1.25 | $0.15 | -88% |
AIM's yearly returns have swung widely, from +284% in 2020 to −94% in 2025. It's down 88% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over AIM on returns for 2026, with the stronger performance.